← All stocks

BioXcel Therapeutics, Inc.

BTAI Scheduled selling only
CIK 0001720893 #4965 in the set updated 17 Sep 2026
Bought (12 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (12 mo)
$43.07K
$43.07K on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 4 sales
Net
−$43.07K
$0.00 against sales at will

By person

7 insiders · 4 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Mehta Vimal
CEO and President
$21.11K (1) scheduled
−$21.11K
69,817
$75.89K
+9,438%
Steinhart Richard I
Chief Financial Officer
$7.43K (1) scheduled
−$7.43K
26,335
$28.63K
Yocca Frank
Chief Scientific Officer
$7.43K (1) scheduled
−$7.43K
26,210
$28.49K
Rodriguez Javier
See Remarks
$7.11K (1) scheduled
−$7.11K
26,838
$29.17K
MACK DAVID J.
Director
20,317
$22.08K
O'Neill Vincent
See Remarks
19,957
$21.69K
+410.8%
Wiley Matthew T.
See Remarks
19,011
$20.66K
+371.4%

No percentages here. This company's share count has moved by a factor of 7.8 over the window, from 5,486,038 to 42,748,364 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Mehta Vimal
20 May 2026
CEO and President
Sold on a plan
19,419
$1.09
$21.11K
Steinhart Richard I
20 May 2026
Chief Financial Officer
Sold on a plan
6,845
$1.09
$7.43K
Rodriguez Javier
20 May 2026
See Remarks
Sold on a plan
6,560
$1.08
$7.11K
Yocca Frank
20 May 2026
Chief Scientific Officer
Sold on a plan
6,845
$1.09
$7.43K

What was left out

Form 4 filings counted 34
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 4
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 152,144
History held since 13 Mar 2018